Vaxxa AB (VAXXA) Fair Value & Analysis
Technology · SE · Market cap 19.2M SEK
Fair value as of: Aug 2, 2026
From 7 valuation models · updated today
Share price +5.2% over the past month.
Below-average quality, and the price sits 73% below our fair value.
What matters now
- The large discount to fair value meets weak quality (31/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (kr 0.5780). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.
How to read this chart
60‑month range kr 0.2724 – kr 14.91 · fair‑value band kr 0.5780 – kr 0.9520 · the kr 0.4420 price screens below the kr 0.7650 fair value. Dashed = 300-day average. As of Aug 2, 2026.
Analysis
Vaxxa AB (VAXXA) currently trades at kr 0.4420, while our model-based Fair Value estimate is kr 0.7650, implying the stock looks roughly 73.1% undervalued today. We read business quality at 31/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Vaxxa AB generated revenue of 92.8M SEK at a net margin of -9.5%. Revenue grew 50.5% year over year. It earns a return on equity of -49.5%. Fundamentals as of Aug 2, 2026
Our scenario range runs from kr 0.5780 (bear case) to kr 0.9520 (bull case); at kr 0.4420, the current price sits below that range. The share trades about 51% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at -27% fair-value upside, at 73%, VAXXA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Multiples (kr 0.9000) versus Asset-Based (kr 0.2300). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vaxxa AB operates an auction platform, vaxxa.se, which provides private individuals and companies to sell and buy used objects in vehicles, machinery, and construction industry. The company was formerly known as Augeo Group AB and changed its name to Vaxxa AB in July 2023. Vaxxa AB was incorporated in 2015 and is based in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Vaxxa AB reported revenue of kr 75.0M in FY2025 versus kr 0 in FY2022. Reported net income was −kr 9.4M in FY2025.
Watch VAXXA: get an alert when its fair value changes →
Peer Group
Software - Application · 773 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Software - Application median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Software - Application stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| SAP SE SAPS | C$12.69 | C$16.26 | +28% |
| Shopify Inc SHOP | C$173.23 | C$20.54 | -88% |
| Uber Technologies, Inc UBER | $72.67 | $51.11 | -30% |
| Salesforce, Inc CRM | $170.77 | $182.10 | +7% |
| ServiceNow, Inc NOW | $107.71 | $33.12 | -69% |
| Cadence Design Systems, Inc CDNS | $384.17 | $80.41 | -79% |
| Snowflake Inc SNOW | $271.87 | $34.04 | -87% |
| Adobe Inc ADBE | $230.61 | $379.48 | +65% |
| Automatic Data Processing, Inc ADP | $241.92 | $177.51 | -27% |
| Intuit Inc INTU | $291.09 | $258.69 | -11% |
Compare Vaxxa AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is Vaxxa AB (VAXXA) overvalued or undervalued?
What is the fair value of VAXXA?
What is the quality score of VAXXA?
What is the revenue of Vaxxa AB (VAXXA)?
What is the net profit margin of VAXXA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Vaxxa AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.